AIMS: We investigated whether venoconstriction by alpha-adrenoceptor stimulation, and venodilation by beta-adrenoceptor stimulation and nitroglycerin are altered in patients with diabetes mellitus (DM). METHODS: Eight male patients with non insulin-dependent DM and eight age-matched control subjects were included. The patients had neither hypertension nor hyperlipidaemia. Noradrenaline (1 to 512 ng min-1 ), isoprenaline (1 to 256 ng min-1 ) and nitroglycerin (0.5 to 128 ng min-1 ) were infused into a dorsal hand vein and its diameter was measured using a linear variable differential transformer. RESULTS: The venoconstricting response to noradrenaline and the venodilating response to nitroglycerin in DM patients were similar to those in control subjects, while the venodilation by isoprenaline was significantly (P<0.05) smaller in DM patients than in control subjects at the dose of 32 ng min-1 or more [32 ng min-1: 11.5% vs 29.8% (DM vs control subjects), 64 ng min-1: 19.0% vs 40.1%, 128 ng min-1: 25.2% vs 49.0%, 256 ng min-1: 34.3% vs 56.7%]. CONCLUSIONS: These data suggested that venoconstriction by alpha-adrenoceptor stimulation and venodilation by nitroglycerin are not altered, whereas venodilation by beta-adrenoceptor stimulation might be impaired in patients with DM.
AIMS: We investigated whether venoconstriction by alpha-adrenoceptor stimulation, and venodilation by beta-adrenoceptor stimulation and nitroglycerin are altered in patients with diabetes mellitus (DM). METHODS: Eight male patients with non insulin-dependent DM and eight age-matched control subjects were included. The patients had neither hypertension nor hyperlipidaemia. Noradrenaline (1 to 512 ng min-1 ), isoprenaline (1 to 256 ng min-1 ) and nitroglycerin (0.5 to 128 ng min-1 ) were infused into a dorsal hand vein and its diameter was measured using a linear variable differential transformer. RESULTS: The venoconstricting response to noradrenaline and the venodilating response to nitroglycerin in DMpatients were similar to those in control subjects, while the venodilation by isoprenaline was significantly (P<0.05) smaller in DMpatients than in control subjects at the dose of 32 ng min-1 or more [32 ng min-1: 11.5% vs 29.8% (DM vs control subjects), 64 ng min-1: 19.0% vs 40.1%, 128 ng min-1: 25.2% vs 49.0%, 256 ng min-1: 34.3% vs 56.7%]. CONCLUSIONS: These data suggested that venoconstriction by alpha-adrenoceptor stimulation and venodilation by nitroglycerin are not altered, whereas venodilation by beta-adrenoceptor stimulation might be impaired in patients with DM.
Authors: F C Huvers; N C Schaper; A J Houben; L Hofstra; P J Kitslaar; P W De Leeuw; A C Nieuwenhuijzen Kruseman Journal: Eur J Clin Invest Date: 1997-05 Impact factor: 4.686
Authors: J E Muller; P H Stone; Z G Turi; J D Rutherford; C A Czeisler; C Parker; W K Poole; E Passamani; R Roberts; T Robertson Journal: N Engl J Med Date: 1985-11-21 Impact factor: 91.245